



**EVIDENCE SYNTHESIS**  
IRELAND



**Cochrane**  
Ireland

## Evidence Synthesis Ireland Fellowship Scheme Review Identification Form

### Review Centre/Group Mentor

Barbara Clyne and Edward W. Gregg, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

### Review title –

WHO Global Diabetes Compact Core Metrics: A Systematic Review of Prevalence.

### Review type and methods

**Review type:** Systematic review of prevalence

**Review methods:** The JBI methodological approach to systematic reviews of prevalence and incidence will be followed. Reporting of this review will be in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The Fellow will learn how to conduct a quantitative synthesis of prevalence estimates, and how to prepare a narrative synthesis of findings.

### Review information

This review will form part of a broader set of planned systematic review projects, related to the Global Diabetes Compact (GDC), a global initiative sponsored by the World Health Organization (WHO). End-users will include patients, researchers, healthcare professionals, and policy-makers. Although no public/patient involvement was considered in the planning of this review, the Fellow will have the opportunity to contribute to the development of a broader set of GDC review projects, which will consider public/patient involvement in the review process.

### Review details

**Background:** The WHO Global Diabetes Compact unites stakeholders around multi-sectoral efforts to reduce the burden that diabetes places on individuals, families, health systems, and national economies. To guide and focus efforts, the Compact established core (e.g., glycaemic control: HbA1c <8%; blood pressure control: BP <140/90 mm Hg) and secondary metrics focusing on reducing levels of risk factors for complications, access to care, and long-term outcomes, while also proposing

health system and policy-level metrics and targets in need of further development.

**Objectives:** The aim of this systematic review is to determine the prevalence of core diabetes metrics, including glycaemic control, blood pressure, and statin use, and will seek to quantify regional and country-level variation in attainment gaps in relation to these indicators.

**Methods:** The review protocol was developed following JBI guidance for systematic reviews of prevalence and incidence, and will be conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Inclusion criteria are informed by the CoCoPop (i.e., Condition, Context, Population) framework. We will include publications involving adult populations, diagnosed with Type 1 or Type 2 diabetes, with no restriction on geographic region. We will include publications that report data from population-based observational studies (i.e., cohorts, cross-sectional surveys). We will search the following databases, from 1 January 2019 to 1 January 2024: PubMed/MEDLINE, Cochrane Library, Embase, EBSCO, LILACS, Web of Science, and the WHO Global Index Medicus. Identified publications will be exported into EndNote, de-duplicated, and imported into Covidence to manage screening and data extraction. Reviewers will use a standardised data extraction form to extract relevant study population, methodological, and outcome data, and to assess the methodological quality of included publications, using the JBI Critical Appraisal tool for studies reporting prevalence data. The primary outcomes of interest concern core diabetes metrics, including glycaemic control, blood pressure control, and statin use.

**Status:** The review protocol will be pre-registered on PROSPERO. The review process has not started. The Fellow will contribute to multiple stages of this review, including: title/abstract screening, full-text review, data extraction, quality and bias assessment, data synthesis (quantitative and narrative), manuscript preparation and publication, policy brief development and other dissemination efforts.

#### **Review current status**

A protocol has been developed. The review has not started yet.

#### **Any specific/desirable requirements for fellow (e.g. clinical expertise, methodological expertise)**

Some knowledge of diabetes and observational research methods would be desirable.

#### **Estimated start and completion dates**

This review is expected to start in January 2024 and to be completed by September/October 2024. The Fellow will also have the opportunity to contribute to the development of the broader set of GDC review projects (i.e., identifying a need for a review, formulating a review question, protocol development and publication).